Continuation of the Consortium for the Study of Chronic Pancreatitis, Diabetes and Pancreatic Cancer Clinical Centers (CPDPC-CCs) (U01 Clinical Trial Optional) | RFA DK 19 009

Opportunity Information: Apply for RFA DK 19 009

This NIH funding opportunity (RFA-DK-19-009) supports the continuation of the Consortium for the Study of Chronic Pancreatitis, Diabetes and Pancreatic Cancer (CPDPC) through awards to Clinical Centers (CCs) under a U01 cooperative agreement mechanism, with clinical trials listed as optional. The overall purpose is not to launch an entirely new program, but to sustain and complete the consortium's ongoing, coordinated clinical research portfolio that has been running since Fall 2015. The focus is on chronic pancreatitis (CP) across ages (children and adults), including patients with acute recurrent pancreatitis (ARP), and on identifying and clarifying factors that raise pancreatic cancer risk in key high-risk groups: people with CP, people with pancreatogenic diabetes (type 3c diabetes, T3cDM), and people with newly diagnosed diabetes. In practical terms, the FOA is aimed at keeping existing longitudinal studies moving forward, ensuring consistent participant characterization and biospecimen collection, and generating findings that improve understanding of disease mechanisms and cancer risk pathways.

Scientifically, the consortium's work centers on deep, longitudinal clinical phenotyping and biological characterization. It seeks to advance understanding of the pathophysiology of chronic pancreatitis and its major downstream complications, including chronic pain, pancreatic exocrine insufficiency, and the development of T3cDM. A major theme is the diabetes and pancreatic cancer association, including targeted work in individuals with newly diagnosed diabetes to better understand (and potentially detect) the subset of patients whose diabetes may be linked to underlying pancreatic cancer biology. By keeping studies harmonized across multiple clinical sites, the consortium is positioned to assemble larger, more diverse cohorts than any single center could, which is important for teasing apart heterogeneity in CP, ARP, diabetes subtypes, and cancer risk signals.

Structurally, the CPDPC is a multi-site network made up of several Clinical Centers plus a separate Coordination and Data Management Center (CDMC). This FOA is specifically for the Clinical Centers. The companion solicitation for the CDMC is RFA-DK-19-504, which covers the centralized coordinating, data, and management functions needed to run a consortium of this type. The expectation is that the CCs and CDMC operate as an integrated unit: clinical sites recruit and follow participants and generate high-quality clinical and biological data, while the coordinating center supports standardized operations, data harmonization, and cross-site analyses.

Because this is a cooperative agreement (U01), the program is meant to be highly collaborative and actively coordinated rather than a set of loosely related independent projects. Clinical Center applicants are expected to bring multidisciplinary teams with the expertise needed to contribute to the consortium's objectives and ongoing studies. That typically implies clinicians and investigators spanning pancreatology/gastroenterology, endocrinology/diabetes, oncology, genetics, epidemiology, biostatistics, imaging, pathology, and translational laboratory science, along with strong clinical research operations. The FOA emphasizes that participating centers should be able to align with the consortium's existing studies and procedures (referenced via the CPDPC clinical studies page) and contribute meaningfully to shared goals such as consistent cohort characterization and collaborative analyses.

A core expectation is open, timely sharing of results within the consortium and active participation in trans-consortium projects that leverage the combined expertise and technologies across sites. In other words, awardees are not just expected to enroll patients and publish locally; they are expected to work across centers, contribute data and specimens according to consortium standards, and help develop collaborative projects that use pooled resources to answer questions that require multi-site scale and coordination.

Eligibility is broad and includes many U.S.-based organizational types commonly eligible for NIH cooperative agreements, such as public and private institutions of higher education, nonprofits (with and without 501(c)(3) status), for-profit organizations (other than small businesses), small businesses, and multiple levels of government (state, county, city/township, special district). It also includes a number of specifically named institution types such as HBCUs, Hispanic-serving institutions, Tribally Controlled Colleges and Universities, and Alaska Native and Native Hawaiian Serving Institutions, among others. Foreign institutions (non-U.S. entities) are not eligible to apply as applicant organizations, but foreign components are allowed under NIH policy, and non-U.S. components of U.S. organizations may participate, which supports international collaboration when it adds value to the science and is structured in compliance with NIH rules.

Key administrative details from the source listing include the sponsoring agency (National Institutes of Health), the funding instrument (cooperative agreement), and the original closing date (2019-12-17). The opportunity is categorized under health-related CFDA numbers 93.393, 93.399, and 93.847. The listing does not specify an award ceiling or the expected number of awards in the provided excerpt, so applicants would need to consult the full FOA for budget limits, project periods, and the precise expectations for scope, milestones, and consortium participation requirements.

• The National Institutes of Health in the education, food and nutrition, health sector is offering a public funding opportunity titled "Continuation of the Consortium for the Study of Chronic Pancreatitis, Diabetes and Pancreatic Cancer Clinical Centers (CPDPC-CCs) (U01 Clinical Trial Optional)" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.393, 93.399, 93.847.
• This funding opportunity was created on 2019-09-26.
• Applicants must submit their applications by 2019-12-17. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.

Apply for RFA DK 19 009

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: